Addressing Treatment Gaps in HER2+ MBC
Unmet needs regarding the selection and sequencing of therapies for patients with HER2-positive metastatic breast cancer.
Optimizing Therapy in HER2+ MBC Across the Globe
A global perspective on managing patients with HER2-positive metastatic breast cancer through multiple lines of therapy based on treatment advances.
Updates in the Management of HER2+ MBC With Brain Metastases
Recent advances in the characterization and treatment of patients with HER2-positive metastatic breast cancer and brain metastases.
Novel Combination Approaches for HER2+ MBC
An overview of novel combination regimens being investigated for the treatment of HER2+ metastatic breast cancer.
T-DXd for HER2+ MBC and Interstitial Lung Disease
Recommendations for managing patients with HER2+ metastatic breast cancer who develop interstitial lung disease, an adverse event of trastuzumab deruxtecan.
Managing TRAEs Associated With Novel HER2+ MBC Therapies
Recommendations for monitoring for and managing adverse events associated with newer therapies being sequenced into HER2+ metastatic breast cancer treatment algorithms.
Updated Data From DESTINY-Breast03 in HER2+ MBC
Practice-changing data from the DESTINY-Breast03 trial evaluating trastuzumab deruxtecan as second-line therapy in HER2-positive metastatic breast cancer presented at ESMO 2021.
Global Trends in HER2+ MBC
Breast oncologists from across the globe react to incidence rates of HER2-positive metastatic breast cancer as they relate to rates of progression to brain metastases and treatment advances.
Black Women With HR+ Breast Cancer Have Worse Outcomes, Despite Similar Recurrence Scores
Benefit of Adjuvant Abemaciclib Increases at 4-Year monarchE Landmark Analysis for Patients With HR+/HER2– High-Risk Early Breast Cancer
Everolimus Plus Adjuvant Endocrine Therapy Fails to Improve iDFS, OS in HR+/HER2- Breast Cancer
Frontline Ribociclib Plus Endocrine Therapy Provides PFS Benefit in Pre/Perimenopausal HR+/HER2- Advanced Breast Cancer
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.